Acetylation site specificities of lysine deacetylase inhibitors in human cells

Nature Biotechnology

Volumn 33, Issue 4, 2015, Pages 415-425

  Schölz, Christian ^a   Weinert, Brian T ^a   Wagner, Sebastian A ^a   Beli, Petra ^a   Miyake, Yasuyuki ^b   Qi, Jun ^c   Jensen, Lars J ^d   Streicher, Werner ^d   McCarthy, Anna R ^e   Westwood, Nicholas J ^f   Lain, Sonia ^e   Cox, Jürgen ^a   Matthias, Patrick ^b   Mann, Matthias ^a   Bradner, James E ^c   Choudhary, Chunaram ^a  

^a University of Copenhagen   (Denmark)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DISEASES; MASS SPECTROMETRY; PROTEINS;

CLINICAL TRIAL; CYTOPLASMIC PROTEINS; DEACETYLASE INHIBITOR; HUMAN CELLS; QUANTITATIVE MASS SPECTROMETRIES; SITE-SPECIFICITY; SPECIFIC SUBSET; SYSTEMS VIEW;

ACETYLATION;

BUFEXAMAC; CYTOPLASM PROTEIN; ENZYME INHIBITOR; HISTONE DEACETYLASE 6; LYSINE DEACETYLASE INHIBITOR; NICOTINAMIDE; SIRTUIN 1; TUBACIN; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN BINDING;

ARTICLE; CELLULAR DISTRIBUTION; GENE DELETION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; ACETYLATION; AMINO ACID SEQUENCE; BINDING SITE; CELL CULTURE; CHEMISTRY; MOLECULAR GENETICS; PEPTIDE MAPPING; PROCEDURES; PROTEIN ANALYSIS;

ACETYLATION; AMINO ACID SEQUENCE; BINDING SITES; CELLS, CULTURED; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDE MAPPING; PROTEIN BINDING; PROTEIN INTERACTION MAPPING;

EID: 84926614325     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3130     Document Type: Article

References (65)

1. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 389, 349-352 (1997).
2. Cheung, W.L., Briggs, S.D. & Allis, C.D. Acetylation and chromosomal functions. Curr. Opin. Cell Biol. 12, 326-333 (2000).
3. Valenzuela-Fernández, A., Cabrero, J.R., Serrador, J.M. & Sanchez-Madrid, F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 18, 291-297 (2008).
4. Yang, X.J. & Seto, E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 31, 449-461 (2008).
5. Haberland, M., Montgomery, R.L. & Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32-42 (2009).
6. Finkel, T., Deng, C.X. & Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature 460, 587-591 (2009).
7. Montgomery, R.L., Hsieh, J., Barbosa, A.C., Richardson, J.A. & Olson, E.N. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc. Natl. Acad. Sci. USA 106, 7876-7881 (2009).
8. Bolden, J.E., Peart, M.J. & Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006).
9. Marks, P.A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 19, 1049-1066 (2010).
10. Archin, N.M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012).
11. Grabiec, A.M., Tak, P.P. & Reedquist, K.A. Function of histone deacetylase inhibitors in inflammation. Crit. Rev. Immunol. 31, 233-263 (2011).
12. Kazantsev, A.G. & Thompson, L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7, 854-868 (2008).
13. Iyer, A., Fairlie, D.P. & Brown, L. Lysine acetylation in obesity, diabetes and metabolic disease. Immunol. Cell Biol. 90, 39-46 (2012).
14. Khan, O. & La Thangue, N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 90, 85-94 (2012).
15. Xu, W.S., Parmigiani, R.B. & Marks, P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26, 5541-5552 (2007).
16. Tan, J., Cang, S., Ma, Y., Petrillo, R.L. & Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3, 5 (2010).
17. Dell'Aversana, C., Lepore, I. & Altucci, L. HDAC modulation and cell death in the clinic. Exp. Cell Res. 318, 1229-1244 (2012).
18. Bradner, J.E. et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6, 238-243 (2010).
19. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265 (2011).
20. Salisbury, C.M. & Cravatt, B.F. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc. Natl. Acad. Sci. USA 104, 1171-1176 (2007).
21. Ong, S.E. et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386 (2002).
22. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840 (2009).
23. Weinert, B.T. et al. Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Reports 4, 842-851 (2013).
24. Sterner, D.E. & Berger, S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64, 435-459 (2000).
25. Drogaris, P. et al. Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation. Sci. Rep. 2, 220 (2012).
26. Buggy, J.J. et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol. Cancer Ther. 5, 1309-1317 (2006).
27. Haggarty, S.J., Koeller, K.M., Wong, J.C., Grozinger, C.M. & Schreiber, S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100, 4389-4394 (2003).
28. Balasubramanian, S. et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026-1034 (2008).
29. Ben-Shahar, T.R. et al. Eco1-dependent cohesin acetylation during establishment of sister chromatid cohesion. Science 321, 563-566 (2008).
30. Unal, E. et al. A molecular determinant for the establishment of sister chromatid cohesion. Science 321, 566-569 (2008).
31. Zhang, J. et al. Acetylation of Smc3 by Eco1 is required for S phase sister chromatid cohesion in both human and yeast. Mol. Cell 31, 143-151 (2008).
32. Deardorff, M.A. et al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature 489, 313-317 (2012).
33. Bitterman, K.J., Anderson, R.M., Cohen, H.Y., Latorre-Esteves, M. & Sinclair, D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277, 45099-45107 (2002).
34. Chen, Y. et al. Quantitative acetylome analysis reveals the roles of SIRT1 in regulating diverse substrates and cellular pathways. Mol. Cell. Proteomics 11, 1048-1062 (2012).
35. Kim, S.C. et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 23, 607-618 (2006).
36. Zhao, S. et al. Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-1004 (2010).
37. Zhang, X. et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol. Cell 27, 197-213 (2007).
38. Uter, W. & Schnuch, A. EMA revokes marketing authorization for bufexamac. Contact Derm. 64, 235-236 (2011).
39. Fukuda, H., Sato, Y., Usami, N., Yokouchi, Y. & Mukai, H. Contact dermatitis caused by bufexamac sparing the eruption of herpes zoster. J. Dermatol. 39, 405-407 (2012).
40. Jeong, J.W. et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111, 709-720 (2002).
41. Dokmanovic, M., Clarke, C. & Marks, P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5, 981-989 (2007).
42. Yang, H. et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130, 1095-1107 (2007).
43. Lain, S. et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13, 454-463 (2008).
44. Anderson, K.A. & Hirschey, M.D. Mitochondrial protein acetylation regulates metabolism. Essays Biochem. 52, 23-35 (2012).
45. Hirschey, M.D., Shimazu, T., Huang, J.Y., Schwer, B. & Verdin, E. SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism. Cold Spring Harb. Symp. Quant. Biol. 76, 267-277 (2011).
46. Wagner, G.R. & Payne, R.M. Mitochondrial acetylation and diseases of aging. J. Aging Res. 2011, 234875 (2011).
47. He, W., Newman, J.C., Wang, M.Z., Ho, L. & Verdin, E. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol. Metab. 23, 467-476 (2012).
48. Eltzschig, H.K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656-665 (2011).
49. Vizcaíno, J.A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223-226 (2014).
50. Nagaraj, N. et al. Deep proteome and transcriptome mapping of a human cancer cell line. Mol. Syst. Biol. 7, 548 (2011).
51. Zhang, Y. et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 28, 1688-1701 (2008).
52. McBurney, M.W. et al. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol. Cell. Biol. 23, 38-54 (2003).
53. Vaquero, A. et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 20, 1256-1261 (2006).
54. Mostoslavsky, R. et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124, 315-329 (2006).
55. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896-1906 (2007).
56. Michalski, A. et al. Mass spectrometry-based proteomics using Q Exactive, a high-performance benchtop quadrupole Orbitrap mass spectrometer. Mol. Cell. Proteomics 10, M111 011015 (2011).
57. Kelstrup, C.D., Young, C., Lavallee, R., Nielsen, M.L. & Olsen, J.V. Optimized fast and sensitive acquisition methods for shotgun proteomics on a quadrupole orbitrap mass spectrometer. J. Proteome Res. 11, 3487-3497 (2012).
58. Waanders, L.F. et al. A novel chromatographic method allows on-line reanalysis of the proteome. Mol. Cell. Proteomics 7, 1452-1459 (2008).
59. Elias, J.E. & Gygi, S.P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207-214 (2007).
60. Emerling, B.M., Weinberg, F., Liu, J.L., Mak, T.W. & Chandel, N.S. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc. Natl. Acad. Sci. USA 105, 2622-2627 (2008).
61. Weinert, B.T. et al. Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine. Cancer Immun. 9, 9 (2009).
62. Szklarczyk, D. et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561-D568 (2011).
63. Cline, M.S. et al. Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2, 2366-2382 (2007).
64. Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091-1093 (2009).
65. Garcia, O. et al. GOlorize: a Cytoscape plug-in for network visualization with Gene Ontology-based layout and coloring. Bioinformatics 23, 394-396 (2007).